Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2020 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG ; Rimassa L. | Future Oncology | 51 | 49 | |
2018 | Cabozantinib in patients with advanced and progressing hepatocellular carcinoma | Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG ; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. | New England Journal of Medicine | 1562 | 1405 | |
2021 | Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab | CHIUN HSU ; Rimassa L.; Sun H.-C.; Vogel A.; Kaseb A.O. | Therapeutic Advances in Medical Oncology | 16 | 14 | |
2020 | Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma | Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG ; El-Khoueiry A.B.; Abou-Alfa G.K. | Clinical Cancer Research | 55 | 44 |